Clinical Trial

A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective is to compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine).

Information:

Principal Investigator	Jose Cruz, MD
Sponsor	National Cancer Institute (NCI)
Type of Trial	Interventional

Contact Us For More Info Or To Apply

5323 S. McColl Rd., Edinburg, TX 78539

[email protected]

(956) 362-2390

Clinical Trial

A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.

Study Status:

Study Purpose:

Information:

Useful Links

For Research Participants

About Us

News & Views